Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage <scp>IV</scp> gastric cancer
Yong Liu(Shanghai First People's Hospital), Han Liang(First Affiliated Hospital of Zhengzhou University), Jingyu Deng(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Jin(Tianjin Medical University Cancer Institute and Hospital), Wenbai Huang(Tianjin Medical University Cancer Institute and Hospital), Hongjie Zhan, Xiaona Wang(Ministry of Education), Li Zhang(Fourth Hospital of Changsha), Baogui Wang(Tianjin Medical University Cancer Institute and Hospital), Xuewei Ding(Tianjin Medical University Cancer Institute and Hospital), Mingzhi Cai(Tianjin Medical University Cancer Institute and Hospital), Ning Liu, Qiang Xue(Sichuan University), Liangliang Wu(Beijing Institute of Aeronautical Materials), Bin Ke(Tianjin Medical University Cancer Institute and Hospital), Ru-Peng Zhang(Tianjin Medical University Cancer Institute and Hospital), Bin Li(Tianjin Medical University Cancer Institute and Hospital), Xue Jun Wang(Tianjin Medical University Cancer Institute and Hospital)
Cited by 3
Related Papers
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18)
|The Journal of Experimental Medicine|2000|582
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
|Nature Medicine|2010|395